Common Contracts
6 similar null contracts by Synaptogenix, Inc., Odyssey Semiconductor Technologies, Inc., PharmaCyte Biotech, Inc., others
KATALYST SECURITIES LLCWrap Technologies, Inc. • June 30th, 2023 • Ordnance & accessories, (no vehicles/guided missiles) • New York
This letter (the “Agreement”) constitutes our understanding with respect to the engagement of Katalyst Securities LLC (“Katalyst”), a broker dealer and member of the Financial Industry Regulatory Authority (“FINRA”) and SIPC, as exclusive placement agent (the “Placement Agent”), by Wrap Technologies, Inc., a publicly traded Delaware corporation (the “Company”), to assist the Company in connection with the placement of Securities in a registered direct offering (as defined below) (the “Offering”) for the Company on an exclusive basis. The Offering will be made pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Act”). The terms and conditions of the Offering are further defined in the Confidential and Non-Binding Summary Term Sheet attached as Exhibit A hereto and dated herewith, which terms and conditions to the extent not in conflict with the terms and conditions of this Agreement are hereby incorporated by reference and expressly made a
KATALYST SECURITIES LLCPharmaCyte Biotech, Inc. • May 11th, 2023 • Biological products, (no disgnostic substances) • New York
This letter (the “Agreement”) constitutes our understanding with respect to the engagement of Katalyst Securities LLC (“Katalyst”), registered broker dealer and member of the Financial Industry Regulatory Authority (“FINRA”) and SIPC, as exclusive placement agent (the “Placement Agent”), by Pharmacyte Biotech, Inc., a publicly traded Nevada corporation (the “Company”), to assist the Company in connection with the private placement financing of Securities (as defined below) (the “Offering”) for the Company on an exclusive basis. The Offering will be made pursuant to the exemptions afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”), and Regulation D promulgated thereunder and applicable state securities laws. The terms and conditions of the Offering are further defined in the Confidential and Non-Binding Summary Term Sheet attached as Exhibit A hereto and dated herewith, which terms and conditions to the extent not in conflict with the terms and conditions
KATALYST SECURITIES LLCSynaptogenix, Inc. • June 16th, 2021 • Pharmaceutical preparations • New York
This letter (the “Agreement”) constitutes our understanding with respect to the engagement of Katalyst Securities LLC (“Katalyst”), registered broker dealer and member of the Financial Industry Regulatory Authority (“FINRA”) and SIPC, by Synaptogenix, Inc., a publicly traded corporation duly organized under the laws of the State of Delaware (the “Company”), to act as a non-exclusive placement agent (the “Placement Agent”) in connection with the private placement of securities of the Company (the “Securities”) (the “Offering”). The Offering will raise up to a total of $12,500,000 (the “Offering Amount”) from the sale of (i) an aggregate of 1,656,287 shares of the Company’s common stock (the “Common Stock”), par value $0.0001 per share (each a “Share”), (ii) Series G warrants to purchase up to an aggregate of 1,656,287 shares of Common Stock, with a term of five (5) years from the date of effectiveness of the registration statement and an exercise price of $8.51. Each Share and Series G
KATALYST SECURITIES LLC NEW YORK, NY 10017 TEL: 212-400-6993 FAX: 212-247-1059 Member: FINRA & SIPCSynaptogenix, Inc. • January 22nd, 2021 • Pharmaceutical preparations • New York
This letter (the “Agreement”) constitutes our understanding with respect to the engagement of Katalyst Securities LLC (“Katalyst”), registered broker dealer and member of the Financial Industry Regulatory Authority (“FINRA”) and SIPC, by Synaptogenix, Inc., a publicly traded corporation duly organized under the laws of the State of Delaware (the “Company”), to act as a non-exclusive placement agent (the “Placement Agent”) in connection with the private placement of securities of the Company (the “Securities”) (the “Offering”). The Offering will raise up to a total of $14,000,000 (the “Offering Amount”) from the sale of (i) an aggregate of 9,335,533 shares of the Company’s common stock (the “Common Stock”), par value $0.0001 per share (each a “Share”), (ii) Series E warrants to purchase up to an aggregate of 9,335,533 shares of Common Stock, with a term of one (1) year from the effectiveness of the registration statement and an exercise price equal to $2.1275, and (iii) Series F warrant
KATALYST SECURITIES LLCOdyssey Semiconductor Technologies, Inc. • January 15th, 2020 • Semiconductors & related devices • New York
This letter (the “Agreement”) constitutes our understanding with respect to the engagement of Katalyst Securities LLC (“Katalyst”), registered broker dealer and member of the Financial Industry Regulatory Authority (“FINRA”) and SIPC, as a non-exclusive placement agent (hereinafter referred to as “Placement Agent”), by Odyssey Semiconductor, Inc., a privately held Delaware corporation (the “Company”), to assist the Company in connection with the private placement of securities (“Securities”) for the Company and Odyssey Semiconductor Technologies, Inc., a privately held Delaware corporation (“Technologies”), which shall become the Company’s parent upon closing the contemplated share exchange, pursuant to which Technologies will occur 100% of the equity securities of the Company in exchange for 5,666,667 shares of common stock of Technologies (the “Share Exchange”). The Company seeks Katalyst to act as a non-exclusive Placement Agent to assist the Company with the private placement finan
KATALYST SECURITIES LLCTrue Drinks Holdings, Inc. • April 30th, 2019 • Medicinal chemicals & botanical products • New York
This letter (the “Agreement”) constitutes our understanding with respect to the engagement of Katalyst Securities LLC (“Katalyst”), registered broker dealer and member of the Financial Industry Regulatory Authority (“FINRA”) and SIPC, as an exclusive placement agent (hereinafter referred to as “Placement Agent”), by Charlie’s Chalk Dust LLC, a Delaware limited liability company (the “Company”) to assist the Company with (i) a minimum Sixteen Million Five Hundred Thousand Dollars ($16,500,000) private placement financing of the Company (the “Offering”) of equity securities by the Company immediately preceding the proposed merger (the “Merger”) with a wholly owned subsidiary (“Acquisition Sub”) of True Drinks Holdings, Inc., a Nevada corporation (“TRUE”) or simultaneously with or immediately after the Merger, and (iii) to assist the Company with other filings required by FINRA, United States Securities and Exchange Commission (the “SEC”) and as required under the Securities Exchange Act
